David Chromy1,2, Mattias Mandorfer1,2, Theresa Bucsics1,2, Philipp Schwabl1,2, Bernhard Scheiner1,2, Caroline Schmidbauer1,2,3, Maximilian Christopher Aichelburg2,4, Peter Ferenci1, Michael Trauner1, Markus Peck-Radosavljevic2,5, Thomas Reiberger1,2. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. 2. Vienna HIV & Liver Study Group, Vienna, Austria. 3. Department of Internal Medicine IV, Wilhelminenspital, Wiener Krankenanstaltenverbund (KAV) der Stadt Wien, Vienna, Austria. 4. Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Vienna, Austria. 5. Department of Internal Medicine and Gastroenterology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Abstract
Background: The treatment of acute hepatitis C (AHC) with direct-acting antiviral agents (DAAs) is considered a cornerstone of hepatitis C virus (HCV) elimination strategies, especially in human immunodeficiency virus (HIV)-infected individuals at high risk of onward transmission. Objective: Optimal treatment regimens and duration for AHC in HIV-coinfected patients remain to be established. Thus, we aimed to evaluate the efficacy and safety of DAA treatment regimens in the setting of AHC. Methods: All HIV-positive patients with a diagnosis of AHC according to the European AIDS Treatment Network (NEAT) consensus attending our clinic after 2014 were included. DAA treatment regimens and duration were based on current recommendations for chronic hepatitis C (CHC) at treatment initiation. Results: Thirty-eight HIV/AHC patients (median age 42.0 years), mostly men who have sex with men (92%), were started on interferon-free regimens. HCV-genotype (GT) was predominately GT-1a (65%). The following DAA regimens were prescribed: ombitasvir/paritaprevir/ritonavir/dasabuvir (42%; 16/38), glecaprevir/pibrentasvir (29%; 11/38), sofosbuvir/ledipasvir (13%; 5/38), ombitasvir/paritaprevir/ritonavir (5%; 2/38), grazoprevir/elbasvir (5%; 2/38) and sofosbuvir/velpatasvir (5%; 2/38). All HIV/AHC patients achieved sustained virologic response 12 weeks after end of treatment (SVR12) (100%; 38/38). DAA-related adverse events were rare. Conclusion: Interferon-free DAA regimens (including 34% pan-genotypic regimens) yielded 100% SVR12 in HIV/AHC individuals if treatment durations similar to CHC are applied.
Background: The treatment of acute hepatitis C (AHC) with direct-acting antiviral agents (DAAs) is considered a cornerstone of hepatitis C virus (HCV) elimination strategies, especially in human immunodeficiency virus (HIV)-infected individuals at high risk of onward transmission. Objective: Optimal treatment regimens and duration for AHC in HIV-coinfectedpatients remain to be established. Thus, we aimed to evaluate the efficacy and safety of DAA treatment regimens in the setting of AHC. Methods: All HIV-positive patients with a diagnosis of AHC according to the European AIDS Treatment Network (NEAT) consensus attending our clinic after 2014 were included. DAA treatment regimens and duration were based on current recommendations for chronic hepatitis C (CHC) at treatment initiation. Results: Thirty-eight HIV/AHCpatients (median age 42.0 years), mostly men who have sex with men (92%), were started on interferon-free regimens. HCV-genotype (GT) was predominately GT-1a (65%). The following DAA regimens were prescribed: ombitasvir/paritaprevir/ritonavir/dasabuvir (42%; 16/38), glecaprevir/pibrentasvir (29%; 11/38), sofosbuvir/ledipasvir (13%; 5/38), ombitasvir/paritaprevir/ritonavir (5%; 2/38), grazoprevir/elbasvir (5%; 2/38) and sofosbuvir/velpatasvir (5%; 2/38). All HIV/AHCpatients achieved sustained virologic response 12 weeks after end of treatment (SVR12) (100%; 38/38). DAA-related adverse events were rare. Conclusion: Interferon-free DAA regimens (including 34% pan-genotypic regimens) yielded 100% SVR12 in HIV/AHC individuals if treatment durations similar to CHC are applied.
Entities:
Keywords:
Hepatitis C virus; coinfection; human immunodeficiency virus; men who have sex with men
Authors: Christoph Boesecke; Daniel Grint; Vincent Soriano; Jens D Lundgren; Antonella d'Arminio Monforte; Victor M Mitsura; Nelly Chentsova; Vesnadarjan Hadziosmanovic; Ole Kirk; Amanda Mocroft; Lars Peters; Jürgen K Rockstroh Journal: Liver Int Date: 2015-04-29 Impact factor: 5.828
Authors: Eric C Seaberg; Mallory D Witt; Lisa P Jacobson; Roger Detels; Charles R Rinaldo; Joseph B Margolick; Stephen Young; John P Phair; Chloe L Thio Journal: Clin Infect Dis Date: 2015-07-14 Impact factor: 9.079
Authors: M Martinello; S Bhagani; E Gane; C Orkin; G Cooke; G J Dore; K Petoumenos; T L Applegate; E Tu; P Marks; N Pagani; J Grebely; M Nelson; G V Matthews Journal: J Viral Hepat Date: 2018-05-08 Impact factor: 3.728
Authors: Susanna Naggie; Kristen M Marks; Michael Hughes; Daniel S Fierer; Christine Macbrayne; Arthur Kim; Kimberly Hollabaugh; Jhoanna Roa; Bill Symonds; Diana M Brainard; John G McHutchison; Marion G Peters; Jennifer J Kiser; Raymond Chung Journal: Clin Infect Dis Date: 2017-04-15 Impact factor: 9.079
Authors: Katja Deterding; Christoph D Spinner; Eckart Schott; Tania M Welzel; Guido Gerken; Hartwig Klinker; Ulrich Spengler; Johannes Wiegand; Julian Schulze Zur Wiesch; Anita Pathil; Markus Cornberg; Andreas Umgelter; Caroline Zöllner; Stefan Zeuzem; Armin Papkalla; Kristina Weber; Svenja Hardtke; Heiko von der Leyen; Armin Koch; Dorothee von Witzendorff; Michael P Manns; Heiner Wedemeyer Journal: Lancet Infect Dis Date: 2016-10-28 Impact factor: 25.071
Authors: Mattias Mandorfer; Philipp Schwabl; Sebastian Steiner; Bernhard Scheiner; David Chromy; Theresa Bucsics; Albert Friedrich Stättermayer; Maximilian Christopher Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Thomas Reiberger; Markus Peck-Radosavljevic Journal: AIDS Date: 2016-04-24 Impact factor: 4.177
Authors: David Wyles; Norbert Bräu; Shyam Kottilil; Eric S Daar; Peter Ruane; Kimberly Workowski; Anne Luetkemeyer; Oluwatoyin Adeyemi; Arthur Y Kim; Brian Doehle; K C Huang; Erik Mogalian; Anu Osinusi; John McNally; Diana M Brainard; John G McHutchison; Susanna Naggie; Mark Sulkowski Journal: Clin Infect Dis Date: 2017-07-01 Impact factor: 9.079
Authors: David Chromy; Philipp Schwabl; Theresa Bucsics; Bernhard Scheiner; Robert Strassl; Florian Mayer; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger; Mattias Mandorfer Journal: Wien Klin Wochenschr Date: 2017-07-25 Impact factor: 1.704
Authors: Lisa Steininger; David Chromy; David Bauer; Benedikt Simbrunner; Teresa Binter; Philipp Schwabl; Caroline Schmidbauer; Michael Trauner; Michael Gschwantler; Mattias Mandorfer; Thomas Reiberger Journal: Wien Klin Wochenschr Date: 2020-12-22 Impact factor: 1.704
Authors: Caroline Schmidbauer; David Chromy; Victor Schmidbauer; David Bauer; Michael Apata; Dung Nguyen; Mattias Mandorfer; Benedikt Simbrunner; Armin Rieger; Florian Mayer; Ralf Schmidt; Heidemarie Holzmann; Michael Trauner; Michael Gschwantler; Thomas Reiberger Journal: Liver Int Date: 2020-03-04 Impact factor: 5.828
Authors: Lara K Marquez; Antoine Chaillon; Kyi Pyar Soe; Derek C Johnson; Jean-Marc Zosso; Andrea Incerti; Anne Loarec; Aude Nguyen; Josephine G Walker; Nyashadzaishe Mafirakureva; Vincent Lo Re Iii; Adriane Wynn; Craig McIntosh; Susan M Kiene; Stephanie Brodine; Richard S Garfein; Peter Vickerman; Natasha K Martin Journal: BMJ Glob Health Date: 2021-02
Authors: David Chromy; David J M Bauer; Benedikt Simbrunner; Matthias Jachs; Lukas Hartl; Philipp Schwabl; Caroline Schwarz; Armin Rieger; Katharina Grabmeier-Pfistershammer; Michael Trauner; Peter Ferenci; Mattias Mandorfer; Michael Gschwantler; Thomas Reiberger Journal: J Viral Hepat Date: 2022-03-15 Impact factor: 3.517
Authors: Omar A Saldarriaga; Bradley Dye; Judy Pham; Timothy G Wanninger; Daniel Millian; Michael Kueht; Benjamin Freiberg; Netanya Utay; Heather L Stevenson Journal: Sci Rep Date: 2021-07-15 Impact factor: 4.379